Introducing BioPass - the ultimate drug delivery solution that will revolutionize CNS disease drugs. With a breakthrough patent, BioPass streamlines the medicine effect process, the effectiveness, and the response. Imagine the medicine getting into the brain and bypassing the BBB in less than 5 minutes, with a fifth less medicine. The best part? BioPass is fully compatible with the regulatory pathway of the FDA, under section 505(b)(2), which means less time to market! With BioPass, invest in the future and make the smart choice for the world. So why wait? Meet the future today and ask us about this exciting innovation. #biopass #drugdelivery #CNSdiseasedrugs #innovation
BioPass Pharma
Biotechnology Research
Developing a revolutionary formulation intended deliver drugs directly into the brain.
About us
An Israeli-based BioPass Pharma Ltd. is developing a revolutionary formulation intended for the treatment of CNS diseases. Utilizing its patented novel formulation of intranasal administration. This technology is designed to deliver drugs directly into the brain by bypassing the BBB. Our novel nasal formulation offers short onset of a non-invasive, painless, easily administered treatment, avoiding gastrointestinal and hepatic presystemic metabolism.
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Type
- Privately Held
- Founded
- 2021